Table 2. Summary of platelet responses... | American Society of Hematology

Table 2.

Summary of platelet responses to romiplostim treatment

Response	All patients (N = 203)
Patients who had a platelet response∗ at any time, n (%)	179 (88.2)
Percentage of time with a platelet response,∗median (IQR)
In the first 6 mo	50.0 (16.7-83.3)
Overall treatment period	78.2 (26.7-90.4)
Percentage of time with platelet counts ≥20 × 10⁹/L above baseline, median (IQR)	80.1 (39.1-92.3)
Patients who achieved a sustained platelet response, n (%)†	11 (5.4)
Time to onset of sustained response, mean ± SD, wk	57.1 ± 36.0

Response	All patients (N = 203)
Patients who had a platelet response∗ at any time, n (%)	179 (88.2)
Percentage of time with a platelet response,∗median (IQR)
In the first 6 mo	50.0 (16.7-83.3)
Overall treatment period	78.2 (26.7-90.4)
Percentage of time with platelet counts ≥20 × 10⁹/L above baseline, median (IQR)	80.1 (39.1-92.3)
Patients who achieved a sustained platelet response, n (%)†	11 (5.4)
Time to onset of sustained response, mean ± SD, wk	57.1 ± 36.0

SD, standard deviation.

Platelet response is defined as a platelet count ≥50 × 10⁹/L without rescue medication use for ITP in the preceding 4 weeks.

Sustained platelet response was defined as consecutive platelet counts ≥50 × 10⁹/L in the absence of any ITP medications for ≥24 weeks.